Nintedanib downregulates the transition of cultured systemic sclerosis fibrocytes into myofibroblasts and their pro-fibrotic activity.
Maurizio CutoloEmanuele GotelliPaola MontagnaSamuele TarditoSabrina PaolinoCarmen PizzorniAlberto SulliVanessa SmithStefano SoldanoPublished in: Arthritis research & therapy (2021)
Nintedanib seems to downregulate in vitro the transition of fibrocytes into myofibroblasts and their pro-fibrotic activity, particularly in cells isolated from Scl70+ILD+ SSc patients.
Keyphrases
- systemic sclerosis
- interstitial lung disease
- idiopathic pulmonary fibrosis
- end stage renal disease
- ejection fraction
- induced apoptosis
- newly diagnosed
- rheumatoid arthritis
- prognostic factors
- anti inflammatory
- peritoneal dialysis
- endothelial cells
- cell cycle arrest
- cell proliferation
- endoplasmic reticulum stress
- signaling pathway
- patient reported
- oxidative stress